These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 15186727)

  • 1. Cytotoxic difference of T cells expanded with anti-CD3 monoclonal antibody in the presence and absence of anti-CD 28 monoclonal antibody.
    Yamada-Ohnishi Y; Azuma H; Urushibara N; Yamaguchi M; Fujihara M; Kobata T; Ikeda H
    Stem Cells Dev; 2004 Jun; 13(3):315-22. PubMed ID: 15186727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phenotypic and functional modulation of interleukin-2-activated peripheral blood mononuclear cells by anti-CD3 and anti-CD28 antibody.
    Yoshino I; Yano T; Miyamoto M; Sugimachi K; Kimura G; Nomoto K
    Lymphokine Cytokine Res; 1993 Aug; 12(4):191-6. PubMed ID: 8218591
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro stimulation and expansion of human tumour-reactive CD8+ cytotoxic T lymphocytes by anti-CD3/CD28/CD137 magnetic beads.
    Teschner D; Wenzel G; Distler E; Schnürer E; Theobald M; Neurauter AA; Schjetne K; Herr W
    Scand J Immunol; 2011 Aug; 74(2):155-64. PubMed ID: 21517928
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interleukin-12 can replace CD28-dependent T-cell costimulation during nonspecific cytotoxic T lymphocyte induction by anti-CD3 antibody.
    Makrigiannis AP; Musgrave BL; Haeryfar SM; Hoskin DW
    J Leukoc Biol; 2001 Jan; 69(1):113-22. PubMed ID: 11200055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CD2-CD48 interactions promote cytotoxic T lymphocyte induction and function: anti-CD2 and anti-CD48 antibodies impair cytokine synthesis, proliferation, target recognition/adhesion, and cytotoxicity.
    Musgrave BL; Watson CL; Hoskin DW
    J Interferon Cytokine Res; 2003 Feb; 23(2):67-81. PubMed ID: 12744772
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphatidylinositol 3-kinase inhibitors prevent mouse cytotoxic T-cell development in vitro.
    Phu T; Haeryfar SM; Musgrave BL; Hoskin DW
    J Leukoc Biol; 2001 May; 69(5):803-14. PubMed ID: 11358990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD3-CD28 costimulation as a means to avoiding T cell preactivation in bispecific monoclonal antibody-based treatment of ovarian carcinoma.
    Mazzoni A; Mezzanzanica D; Jung G; Wolf H; Colnaghi MI; Canevari S
    Cancer Res; 1996 Dec; 56(23):5443-9. PubMed ID: 8968099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Generation propagation, and targeting of human CD4+ helper/killer T cells induced by anti-CD3 monoclonal antibody plus recombinant IL-2. An efficient strategy for adoptive tumor immunotherapy.
    Nishimura T; Nakamura Y; Takeuchi Y; Tokuda Y; Iwasawa M; Kawasaki A; Okumura K; Habu S
    J Immunol; 1992 Jan; 148(1):285-91. PubMed ID: 1345787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28- T cells and inhibit both T-cell proliferation and CTL function.
    Filaci G; Fravega M; Negrini S; Procopio F; Fenoglio D; Rizzi M; Brenci S; Contini P; Olive D; Ghio M; Setti M; Accolla RS; Puppo F; Indiveri F
    Hum Immunol; 2004 Feb; 65(2):142-56. PubMed ID: 14969769
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of tetravalent bispecific CD19xCD3 recombinant antibody construct and CD28 costimulation on lysis of malignant B cells from patients with chronic lymphocytic leukemia by autologous T cells.
    Reusch U; Le Gall F; Hensel M; Moldenhauer G; Ho AD; Little M; Kipriyanov SM
    Int J Cancer; 2004 Nov; 112(3):509-18. PubMed ID: 15382079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo studies using bispecific antibodies (anti-CD3 x anti-idiotype) and CD28-induced costimulation in the BCL1 lymphoma.
    Demanet C; Brissinck J; De Jonge J; Thielemans K
    J Hematother; 1995 Oct; 4(5):363-8. PubMed ID: 8581370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid induction of cytolytic T cells via CD28 stimulation for cellular immunotherapy.
    Blum S; Milesi R; Tratkiewicz J; Olive D; Gallati H; Cerottini JC; von Fliedner V
    Ther Immunol; 1994 Jun; 1(3):143-52. PubMed ID: 7584490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Helper effector function of human T cells stimulated by anti-CD3 mAb can be enhanced by co-stimulatory signals and is partially dependent on CD40-CD40 ligand interaction.
    Kwekkeboom J; de Rijk D; Kasran A; Barcy S; de Groot C; de Boer M
    Eur J Immunol; 1994 Mar; 24(3):508-17. PubMed ID: 7510232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Interleukin-12 restores and promotes the T-cell immune function inhibited by 5-fluorouracil].
    Chi PD; Li L; Fan YY; Wu CY
    Ai Zheng; 2007 Aug; 26(8):801-8. PubMed ID: 17697537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stimulation via the CD3 and CD28 molecules induces responsiveness to IL-4 in CD4+CD29+CD45R- memory T lymphocytes.
    Damle NK; Doyle LV
    J Immunol; 1989 Sep; 143(6):1761-7. PubMed ID: 2570801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ex vivo expansion of dendritic-cell-activated antigen-specific CD4+ T cells with anti-CD3/CD28, interleukin-7, and interleukin-15: potential for adoptive T cell immunotherapy.
    Chen HW; Liao CH; Ying C; Chang CJ; Lin CM
    Clin Immunol; 2006 Apr; 119(1):21-31. PubMed ID: 16406844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of resting T cells against the CA 72-4 tumor antigen with an anti-CD3/CA 72-4 bispecific antibody in combination with a costimulatory anti-CD28 antibody.
    Hombach A; Mathas S; Jensen M; Tillmann T; Menges M; Diehl V; Kruis W; Pohl C
    Anticancer Res; 1997; 17(3C):2025-32. PubMed ID: 9216660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impaired interleukin-2 synthesis and T cell proliferation following antibody-mediated CD3 and CD2 or CD28 cross-linking in trans: evidence that T cell activation requires the engagement of costimulatory molecules within the immunological synapse.
    Watson CL; Furlong SJ; Hoskin DW
    Immunol Invest; 2008; 37(1):63-78. PubMed ID: 18214800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expanded tumor-reactive CD4+ T-cell responses to human cancers induced by secondary anti-CD3/anti-CD28 activation.
    Li Q; Furman SA; Bradford CR; Chang AE
    Clin Cancer Res; 1999 Feb; 5(2):461-9. PubMed ID: 10037198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD28 ligation by monoclonal antibodies or B7/BB1 provides an accessory signal for the cyclosporin A-resistant generation of cytotoxic T cell activity.
    Van Gool SW; de Boer M; Ceuppens JL
    J Immunol; 1993 Apr; 150(8 Pt 1):3254-63. PubMed ID: 7682237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.